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Abstract: In the current study, cisplatin loaded (Poly(lactic-co-glycolicacid)) (PLGA) stabilized with 4-phenylphenacylbromide based
surfactants nanoparticles were developed for drug delivery applications. For the course of this study four new 4-phenylphenacylbromide
based compounds abbreviated as PA(C2)3, PA(C8)3, PAC16 and PAC18 have been synthesized by the reaction of 4-phenylphenacylbromide
with various long chain amines. The new surfactants were characterized with 1H and 13C NMR and FTIR spectroscopy. The critical micelle
concentration (CMC) of newly synthesized surfactants are in the range of 0.024–0.091 mM. The newly synthesized surfactants have
been incorporated in PLGA based nanoparticles and are used for drug encapsulation and delivery of cisplatin. The drug encapsulation
efficiency for newly fabricated nanoparticles was found to be in the range of 65 ± 1.5 to 67 ± 1.6%, the drug loading was observed in the
range of 1.96 ± 0.11 to 2.31 ± 0.19%, whereas the maximum drug release was found to be 85.1 ± 1.1%.
Key words: Cisplatin, surfactants, drug delivery, PLGA nanoparticles

1. Introduction:
Surfactants are a very diverse class of amphiphilic molecules that find applications in almost every field of life. Their
innovative nature and striking properties have always been a source of attraction for chemists and biochemists. Surfactants
can be obtained from various sources; they can be naturally occurring or synthetic. The naturally occurring surfactants
include glycerol-based lipids, which are vital components of cell membranes. Historically, the soaps were the first type
of surfactants that were discovered, manufactured, and used by humans [1]. All detergents, wetting agents, emulsifiers,
foaming agents, corrosion inhibitors, antistatic agents etc. are usually surfactants [2,3]. The first surfactants discovered
in living systems were pulmonary surfactants, which have an important role in lowering the surface tension in alveoli in
lungs. From detergents to cosmetics, surfactants come in handy for human use in every possible way. Their surface-active
properties and the tendency to alter surface tension of the medium make them a unique and diversely applicable class of
compounds [4–6].
Poly(D,L-lactic-co-glycolic acid) (PLGA) is a copolymer of poly(lactic acid) (PLA) and poly(glycolic acid) (PGA). It
is been explored by many investigators for developing nanoparticles (NPs) for drug delivery (DD) applications for cancer
diagnosis and therapy due to its high biocompatibility and biodegradability [7, 8].
Temperature-sensitive, targetable cisplatin nanocarriers based on poly(propylene succinate) copolymers with
poly(ethyleneglycol) (PPSu-PEG) were prepared and evaluated in vitro for their potential for a more selective delivery of
cisplatin to tumours using local hyperthermia was reported earlier. One-pot melt-polymerization under vacuum was used
to prepare the copolymer and loaded with cisplatin using double emulsion method [9].
In a recent study, folate-poly(ethylene glycol)-poly(propylene succinate) nanoparticles (FA-PPSu-PEG-NPs) were
developed and used as a vehicle for targeted delivery of the anticancer drug paclitaxel in breast and cervical cancer cell
lines. FA-PPSu-PEG-NPs can also be used as vehicles for other anticancer drugs [10]. The drug release profile shows a
biphasic nature, with a rapid release during the first 24 h, followed by a prolonged release phase, reaching a plateau after
96 h.
It is common to produce PLGA NPs through nanoprecipitation method, also called the solvent-evaporation or solventswitch method [11]. Using this technique, usually NPs sizes between 100 and 200 nm is obtained depending on the solvent
used, solvent ratio and polymer-drug concentration. It offers a good reproducibility and particle stability [7,12]. Despite
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these advantages, the stability of NPs to some extent becomes limited when polymeric NPs are loaded with drugs. One
way to increase the NPs colloidal stability is the use of amphiphilic substances called surfactants. Different investigators
used range of surfactants from nonionic to ionic (cationic or anionic) [13, 14]. In a recent study [15] different surfactant,
i.e. PVA, Pluronic F68, Pluronic F127 and polysorbates (Tween 20, Tween 80) were used in the preparation of PLGA NPs
loaded with protein kinase C inhibitor and the result shows the drug encapsulation efficiency varied from 31 to 75% with a
drug loading of 1.3%–2% and partially hydrolyzed PVA was the surfactant of choice. Similarly in another recent study [16],
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Scheme 1. Reaction scheme shows the synthesis of PA(C2)3.

Scheme-1

Reaction scheme shows the synthesis of PA(C2)3
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absorbance measurement of the reaction product of released cis-platin and OPDA. The product was obtained in 10–5 M
HCl at 90 °C in 30 min. The percentage of entrapped cisplatin (drug encapsulation efficiency) was measured by dissolving
a dried pellet of known weight with 100 μL of DMF by vortexing for 30 min. For drug release study, the encapsulated cisplatin was released by suspending all sets of prepared nanoparticles in phosphate buffer saline at pH 7.4 one by one for
several hours. The mixture was centrifuged at 14000 rpm for 15 min and the resulting supernatant was checked for the
presence of cisplatin by UV-Vis absorbance around 710 nm.
3. Results and discussion
3.1 Schematic structure of synthesized surfactants
Four new 4-phenyl phenacylbromide based compounds have been synthesized by reacting the precursor with different
long chain tertiary and primary amines and three of these compounds are regarded as surfactants. These surfactants are
used in the drug delivery application of cis-platin along with PLGA. The structure of 4-phenyl phenacylbromide and the
synthesized surfactants are shown in Figures 1 and 2. The physical data of these surfactants are summed up in the Table 2.
3.2 Characterization
3.2.1 Characterization by physical parameters
The newly synthesized series can be characterized in terms of physical parameters such as physical state, color, melting
point etc., as illustrated in Table 3. All newly synthesized compounds are solids at room temperature and have sharp
melting points. All of these shows moderate solubility in common organic solvents as well as in water.
3.2.2 Characterization by spectroscopic data
All new synthesized 4-phenylphencylbromide based compounds have been characterized by 1H and 13C NMR spectroscopy
and FTIR spectroscopy. The successful synthesis of all 4 surfactants has been confirmed by spectroscopic techniques.
Table 1. Composition of prepared nanoparticle.
Serial No.

Formulation

Surfactant

PLGA

Cis-platin

1.

PA(C2)3-PLGA

10 mg

100 mg

5 mg

2.

PA(C8)3-PLGA

10 mg

100 mg

5 mg

3.

PAC16-PLGA

10 mg

100 mg

5 mg

4.

PAC18-PLGA

10 mg

100 mg

5 mg

O
Br

Figure 1. Structure of 4-phenyl phenacylbromide.

O
N+RR'R''

Figure 2. Schematic structure of newly synthesized compounds where,
R= C2H5, R’= C2H5, R’’= C2H5 for PA(C2)3 R= C8H17, R’= C8H17, R’’= C8H17
for PA(C8)3 R= C16H33, R’= H for PAC16. R= C18H37, R’= H for PAC18
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Table 2. Description of newly synthesized compounds.
Reactants
S#

1st reactant

Product
2nd reactant

Molecular
formula

Percentage
yield

Structural formula
O

1.

Phenylphenacyl
bromide

2.

Phenylphenacyl
bromide

Triethyl amine

C20H26ON

N+

64.59%

O

Trioctyl amine

C38H62ON

N+(C8H17)3

57.41%

O

3.

4.

Phenylphenacyl
bromide

Hexadecyl
amine

Phenylphenacyl
bromide

Octadecyl
amine

C30H44ON

NH(C16H33)

78.27%

O

C32H48ON

77.83%
NH(C18H37)

Table 3. Physical characteristics of newly synthesized compounds.
Serial No.

Compound
abbreviation

1.

PA(C2)3

2.

PA(C8)3

3.

PAC16

4.

PAC18

Molecular mass
296 g/mol

Melting point

Solubility

Color

H2O,CHCl3, Acetone, DMSO,DMF

Light brown

H2O,CHCl3, Acetone, DMSO,DMF

Brown

548 g/mol

78°C
156°C

434 g/mol

134°C

H2O,CHCl3, Acetone, DMSO,DMF

White

462 g/mol

139°C

H2O,CHCl3, Acetone, DMSO,DMF

White

3.2.3 1H NMR Spectroscopy
The 1H NMR spectrum was recorded for all 4-phenyl phenacylbromide based compounds. The spectral data is found to
be in accordance with the predicted structure hence it can be said that the synthesis of new surfactants was successful.
The 1H NMR spectrum of PA(C8)3 is shown in Figure 3. The characteristic peaks and their multiplicity are listed in Table
4. 1H-NMR spectra of novel synthesized compounds (PA(C2)3, PA(C8)3, PAC16 and PAC18) show characteristics chemical
shifts: δ (ppm): 7.42–8.07 (m), 7.44–8.09 (m), 7.42–7.92 (m) and 7.42–8.02 (m) for aromatic-H respectively, 4.50 (s), 4.76
(s), 4.50 (s) and 4.56 (s) for CH2 respectively, 2.38 (q), 2.39 (t), 2.36 (m) and 2.34 (m) for CH2-N respectively, 1.27 (m), 1.33
(m) and 1.33 (m) for long chain respectively, and 1.25 (t), 0.90 (m), 0.96 (m) and 0.97 (m) for CH3 respectively.
3.2.4 13C NMR spectroscopy
The number and types of groups of carbon atoms present in the compound are confirmed by 13C NMR spectroscopy and
the predicted structure for the new surfactants can be justified by elaborating the NMR data. The spectrum of PA(C8)3 is
shown in Figure 4. The characteristic shifts are illustrated in Table 5. The13C-NMR spectra of novel synthesized surfactants
(PA(C2)3, PA(C8)3, PAC16 and PAC18) show characteristic chemical shifts: δ (ppm): 127–145, 127–140, 127–141 and 127–
141.5 for aromatic carbon, 195.5, 196, 196.5 and 197 for (C=O), 70.5, 70, 69.8 and 68.5 for CH2, 60.5, 60, 58 and 59 for C-N,
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Figure 3. 1H NMR spectrum of PA(C8)3 surfactant.
Table 4. 1HNMR data of Newly synthesized compounds.
Bonding
Tail

Head

PA(C2)3

PA(C8)3

PAC16

PAC18

Aromatic H

7.42–8.07 (m)

7.44–8.09(m)

7.42–7.92 (m)

7.42–8.02 (m)

CH2

4.50 (s)

4.76 (s)

4.50 (s)

4.56 (s)

CH2 -N

2.38 (q)

2.39 (t)

2.36 (m)

2.34 (m)

Long chain

-

1.27 (m)

1.33 (m)

1.33 (m)

CH3

1.25 (t)

0.90 (m)

0.96 (m)

0.97 (m)

21–32, 22–30.1, 22.8–29.7 for long chain carbon, 10.5, 14, 14.5 and 14 for CH3, respectively. These characteristic peaks
confirm the formation of novel surfactants.
3.2.5 FTIR spectroscopy
The FTIR spectrum was recorded for all four newly synthesized surfactants is given as: The peaks observed at (2917 and
2842 cm–1), (2915 and 2843 cm–1), (2919 cm–1 and 2846 cm–1) and (2918 and 2848 cm–1) corresponds to sp3 C-H stretch in
IR spectra of PA(C2)3, PA(C8)3, PAC16 and PAC18, respectively. The vibrational band for (C=O) appears at 1681 cm–1, 1682
cm–1, 1682 cm–1 and 1683 cm–1, for (C=C) at 1604 cm–1, 1603 cm–1, 1601 cm–1, 1600 cm–1, for (C-N) at 1239 cm–1, 1237 cm–1,
1236 cm–1 and 1235 cm–1in the spectra of synthesized surfactants (PA(C2)3, PA(C8)3, PAC16 and PAC18), respectively. The
CH3 and CH2 bending vibrations of PA(C2)3 appears at 1385 and 1463 cm–1, for PA(C8)3 at 1388 and 1467 cm–1, for PAC16 at
1384 and 1465 cm–1, for PAC18 at 1386 and 1462 cm–1. These peaks confirm the formation of novel synthesized surfactants.
The FTIR data of newly synthesized surfactants is summed up in Table 6.
3.3 CMC values
The critical micelle concentration (CMC) i.e. the concentration of a surfactant in a solution at which micelle formation starts,
decreases with the increase in chain length of the surfactants. The CMC of newly synthesized 4-phenyl phenacylbromide
based surfactants has been determined using tensiometric method. Different dilutions were prepared from 1 mM stock
solution of every surfactant and surface tension for each of these dilutions was recorded by a force tensiometer calibrated
with distilled water. A graph was plotted between surface tension in nm–1 on y-axis and concentration in mM on x-axis,
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Figure 4 . 13C NMR spectrum of PA(C8)3 surfactant.

and CMC was identified as the intersecting point of two lines, the linear declining slope, and the baseline of minimal
surface tension. The CMC plots for the new compounds are displayed in Table 7. Difference in hydrophobic chain length
results in different CMC values [1,3]. Note that the carbon number in long chain of PA(C8)3 is the highest (24 carbons in 3
long chains), but the chain length is shorter that is why CMC value is high. Whereas for PAC16 and PAC18 surfactants the
long chain carbons are lesser (16 and 18 carbons per chain) but the CMC value is lower as compared to PA(C8)3 surfactant.
This makes the PAC18 surfactant most useful in terms of CMC.
3.4 Drug delivery
The drug delivery application of newly synthesized surfactants was carried out using the well-known anticancer drug cisplatin. The drug was encapsulated in PLGA nanoparticles along with surfactants. Surfactants act as encapsulating agents
for the drug as well as stabilizers for nanoparticles which were lyophilized and stored for further study. Later the drug
release was studied by suspending the resultant nanoparticles in phosphate buffer saline of pH 7.4.
3.4.1 Drug delivery application
The initial CP concentration was taken as 5 mg. The drug encapsulation efficiency can be calculated by determination of
encapsulated CP amount by using the following relation.

𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝐶𝐶𝐶𝐶 𝑖𝑖𝑖𝑖 𝑁𝑁𝑁𝑁𝑁𝑁
𝐷𝐷𝐷𝐷𝐷𝐷 = 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝐶𝐶𝐶𝐶 𝑖𝑖𝑖𝑖 𝑁𝑁𝑁𝑁𝑁𝑁 𝑥𝑥 100
𝐷𝐷𝐷𝐷𝐷𝐷 = 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝐶𝐶𝐶𝐶 𝑥𝑥 100
𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑜𝑜𝑜𝑜 𝐶𝐶𝐶𝐶
The drug loading content (DLC) can be calculate using the following relationship.
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑜𝑜𝑜𝑜 𝐶𝐶𝐶𝐶 𝑖𝑖𝑖𝑖 𝑁𝑁𝑁𝑁𝑁𝑁
𝐷𝐷𝐷𝐷𝐷𝐷 = 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑜𝑜𝑜𝑜 𝐶𝐶𝐶𝐶 𝑖𝑖𝑖𝑖 𝑁𝑁𝑁𝑁𝑁𝑁 𝑥𝑥 100
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑜𝑜𝑜𝑜 𝑁𝑁𝑁𝑁𝑁𝑁
𝐷𝐷𝐷𝐷𝐷𝐷 =
𝑥𝑥 100
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑜𝑜𝑜𝑜 𝑁𝑁𝑁𝑁𝑁𝑁

The drug encapsulation efficiency for the prepared surfactants coated PLGA nanoparticle formulations range from
65%–67%, which are very similar to each other. The ease of micelle formation is depicted in the calculated encapsulation
efficiency for the formulations prepared using surfactants. The drug loading content was found in the range of 1.96 to 2.31%
and very similar for all NPs-surfactant formulations. The results shown above are also comparable to those of the already
carried out experiments with cisplatin-PLGA supported with other compounds (mPEG etc) where DLC was found in the
range of 1.99%–2.0% [20]. In a recent study [21] cisplatin-loaded PLGA NPs supported with chitosan shows the DLC of
6.67 ± 0.9% with an drug encapsulation efficiency of 62.99 ± 2.01%, for human epidermal growth factor receptor 2 targeted
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Table 5. 13C NMR data of newly synthesized compounds.
Bonding
Tail

Head

PA(C2)3

PA(C8)3

PAC16

PAC18

Aromatic C

127–143

127–145

127–141

127–141.5

C=O

195.5

196

196.5

197

CH2

72.5

73.5

72.8

72.5

C-N

50.5

52.2

53

52.5

Long chain C

-

22.5–31.6

22–30.1

22.8–29.7

CH3

10.5

14.4

14.5

14

Table 6. FTIR data of newly synthesized compounds.
Bonding

PA(C2)3
(cm–1)

PA(C8)3
(cm–1)

PAC16
(cm–1)

PAC18
(cm–1)

C-N

1239

1237

1236

1235

C=O

1681

1682

1682

1683

C=C

1604

1603

1601

1600

CH2 bending

1463

1467

1465

1462

sp C-H stretch

2917, 2842

2915, 2843

2919, 2846

2918, 2848

CH3 bending

1385

1388

1384

1386

3

Table 8. Drug delivery parameters for cisplatin loaded PLGA-surfactant nanoparticles.
Serial No.

Nanoparticle
formulation

Drug encapsulation
efficiency (%)

Drug loading
content (%)

Drug
released (%)

1.

PA(C2)3-PLGA

65 ± 1.5

1.96 ± 0.11

85.1 ± 1.1

2.

PA(C8)3-PLGA

67 ± 1.6

2.12 ± 0.20

82.2 ± 2.1

3.

PAC16-PLGA

66 ± 1.8

2.07 ± 0.14

81.1 ± 1.7

4.

PAC18-PLGA

66 ± 2.1

2.31 ± 0.19

80.7 ± 1.9

Table 7. CMC values of newly synthesized compounds.
S#

Surfactants

CMC (mM)

1.

PA(C2)3

0.091

2.

PA(C8)3

0.028

3.

PAC16

0.026

4.

PAC18

0.024

ovarian cancer therapy, similarly the other study shows the DLC of 3.9% and DEE of 72% for PLGA-mPEG NPs loaded
with cisplatin [22]. The release of drug from cisplatin loaded PLGA-surfactant Nps was studied for 96 h and the results
shows the release of drug was achieved up to 80.7 to 85.1% which better than the reported previously [22] where nearly 85
% was achieved in 120 h, similarly the other study shows the drug release of less than 40% in 70 h [21]. Similarly in another
study [23], the percent loading of the PLGA-mPEG nanoparticles with cisplatin was shown to be significant (1%–2.5%
w/w). In the proposed method, a modified double emulsion method was used to prepare PLGA-mPEG nanoparticles of
cisplatin, which resulted in improved cisplatin loading in the PLGA-mPEG nanoparticles.
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The drug encapsulation efficiency (DEE), LDC and drug release calculated for all nanoparticle formulations is listed
in Table 8.
Conflicts of interest
The authors declare that they have no conflict of interest.
References
1.

Rosen MJ, Kunjappu JT. Surfactants and Interfacial Phenomena, 4th Edition. John Wiley & Sons Ltd, New York 2012. doi:
10.1002/9781118228920

2.

Schramm LL, Stasiuk EN, Marangoni DG. Surfactants and their applications. Annual Reports Section “C” (Physical Chemistry) 2003; 99:
3-48. doi: 10.1039/B208499F

3.

Ghosh S, Ray A, Pramanik N. Self-assembly of surfactants: An overview on general aspects of amphiphiles. Biophysical Chemistry 2020;
265: 106429. doi: 10.1016/j.bpc.2020.106429

4.

Pandey V, Kohli S. Lipids and Surfactants: The inside story of lipid-based drug delivery systems. Critical Reviews in Therapeutic Drug
Carrier Systems 2018; 35 (2): 99-155. doi: 10.1615/CritRevTherDrugCarrierSyst.2018016710

5.

Gerola AP, Costa PFA, Quina FH, Fiedler HD, Nome F. Zwitterionic surfactants in ion binding and catalysis. Current Opinion in Colloid
& Interface Science 2017; 32: 39-47. doi: 10.1016/j.cocis.2017.10.002

6.

Chaudhari SP, Dugar RP. Application of surfactants in solid dispersion technology for improving solubility of poorly water soluble drugs.
Journal of Drug Delivery Science and Technology 2017; 41: 68-77. doi: 10.1016/j.jddst.2017.06.010

7.

Mir M, Ahmed N, Rehman AU. Recent applications of PLGA based nanostructures in drug delivery. Colloids and Surfaces B: Biointerfaces
2017; 159: 217-31. doi: 10.1016/j.colsurfb.2017.07.038

8.

Nanaki S, Siafaka P, Zachariadou D, Nerantzaki M, Giliopoulos DJ et al. PLGA/SBA 15 mesoporous silica composite microparticles loaded
with paclitaxel for local chemotherapy. European Journal of Pharmaceutical Sciences 2017; 99: 3R 44.

9.

Spiridoula K, George M, Sofia P, Evangelos K, Dimitrios B et al. PPSu-PEG Copolymers and their Application in the Preparation of
Cisplatin-loaded Nanoparticles. Current Nanoscience 2011; 7 (4): 503-09. doi: 10.2174/157341311796196880

10.

Tsolou A, Angelou E, Didaskalou S, Bikiaris D, Avgoustakis K et al. Folate and pegylated aliphatic polyester nanoparticles for targeted
anticancer drug delivery. International Journal of Nanomedicine 2020; 15: 4899-918. doi: 10.2147/IJN.S244712

11.

Barichello JM, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the
nanoprecipitation method. Drug Development and Industrial Pharmacy 1999; 25 (4): 471-76. doi: 10.1081/DDC-100102197

12.

Martínez Rivas CJ, Tarhini M, Badri W, Miladi K et al. Nanoprecipitation process: From encapsulation to drug delivery. International
Journal of Pharmaceutics 2017; 532 (1): 66-81. doi: 10.1016/j.ijpharm.2017.08.064

13.

Heinz H, Pramanik C, Heinz O, Ding YF, Mishra RK et al. Nanoparticle decoration with surfactants: Molecular intercations, assmbly, and
applications. Surface Science Reports 2017; 72 (1): 1-58. doi: 10.1016/j.surfrep.2017.02.001

14.

Swider E, Koshkina O, Tel J, Cruz LJ, de Vries IJM et al. Customizing poly(lactic-co-glycolic acid) particles for biomedical applications.
Acta Biomaterialia 2018; 73: 38-51. doi: 10.1016/j.actbio.2018.04.006

15.

Shkodra-Pula B, Grune C, Traeger A, Vollrath A, Schubert S et al. Effect of surfactant on the size and stability of PLGA nanoparticles
encapsulating a protein kinase C inhibitor. International Journal of Pharmaceutics 2019; 566: 756-64. doi: 10.1016/j.ijpharm.2019.05.072

16.

Khatua A, Prasad A, Priyadarshini E, Virmani I, Ghosh l et al. CTAB-PLGA curcumin nanoparticles: preparation, biophysical
characterization and their enhanced antifungal activity against phytopathogenic fungus pythium ultimum. Chemistry Select 2020; 5 (34):
10574-80. doi: 10.1002/slct.202002158

17.

Sanna V, Roggio AM, Siliani S, Piccinini M, Marceddu S et al. Development of novel cationic chitosan-and anionic alginate-coated poly(D,Llactide-co-glycolide) nanoparticles for controlled release and light protection of resveratrol. International journal of nanomedicine 2012;
7: 5501-16. doi: 10.2147/IJN.S36684

18.

Zhou J, Romero G, Rojas E, Ma L, Moya S et al. Layer by layer chitosan/alginate coatings on poly(lactide-co-glycolide) nanoparticles for
antifouling protection and Folic acid binding to achieve selective cell targeting. Journal of Colloid and Interface Science 2010; 345 (2):
241-47. doi: 10.1016/j.jcis.2010.02.004

19.

Anilanmert B, Yalçin G, Ariöz F, Dölen E. The spectrophotometric determination of cisplatin in urine, using o-phenylenediamine as
derivatizing agent. Analytical Letters 2001; 34 (1): 113-23. doi: 10.1081/AL-100002709

1794

UMAR et al. / Turk J Chem
20.

Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer
agents. International Journal of Nanomedicine 2011; 6: 877-95. doi: 10.2147/IJN.S18905

21.

Domínguez-Ríos R, Sánchez-Ramírez DR, Ruiz-Saray K, Oceguera-Basurto PE, Almada M et al. Cisplatin-loaded PLGA nanoparticles for
HER2 targeted ovarian cancer therapy. Colloids and Surfaces B: Biointerfaces 2019; 178: 199-207. doi: 10.1016/j.colsurfb.2019.03.011

22.

Cheng L, Jin C, Lv W, Ding Q, Han X. Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of
ovarian cancer. PLoS One 2011; 6 (9): e25433. doi: 10.1371/journal.pone.0025433

23.

Gryparis EC, Mattheolabakis G, Bikiaris D, Avgoustakis K. Effect of conditions of preparation on the size and encapsulation properties of
PLGA-mPEG nanoparticles of cisplatin. Drug Delivery 2007; 14 (6): 371-80. doi: 10.1080/10717540701202937

1795

